Literature DB >> 32462681

Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer.

Alexander P Stark1, Jeannelyn S Estrella2, Yi-Ju Chiang1, Prajnan Das3, Bruce D Minsky3, Mariela A Blum Murphy4, Jaffer A Ajani4, Paul Mansfield1, Brian D Badgwell1, Naruhiko Ikoma1.   

Abstract

BACKGROUND AND OBJECTIVES: It is unknown whether the degree of response to preoperative therapy correlates with locoregional recurrence (LR) or distant recurrence (DR) after resection of gastric cancer.
METHODS: Patients who underwent resection of gastric adenocarcinoma following chemotherapy and chemoradiation (1995-2015) were reviewed. The tumor regression grade (TRG) was defined by the percentage of viable tumor cells in the specimen (TRG0 = 0%; TRG1 = 1%-2%; TRG2 = 3%-50%; TRG3 ≥ 50%). The relationships among TRG, recurrence-free survival (RFS), LR, and DR were examined.
RESULTS: Two hundred forty-seven patients met the inclusion criteria (TRG0, 52 [21%]; TRG1, 49 [20%]; TRG2, 98 [40%]; TRG3, 48 [19%]). LR and DR occurred in 6.1% and 32.0% of patients, respectively. No patient with TRG0 experienced LR. R1 resection (6%-15%) and LR (6%-8%) rates were similar among TRG1-3 patients. R1 resection was associated with LR (hazard ratio [HR], 17.85; P < .001). ypN status (HR, 2.44; P = .004) and linitis plastica (HR, 2.90; P < .001) were associated with DR. TRG was not independently associated with RFS, LR, or DR.
CONCLUSIONS: TRG0 imparted excellent local control. However, TRG1-3 patients had similar R1 resection rates and therefore similar LR. DR is associated with ypN status and linitis plastica, not TRG.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  gastric cancer; neoadjuvant; radiation therapy; recurrence; tumor regression grade

Year:  2020        PMID: 32462681     DOI: 10.1002/jso.25984

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Prognostic value and clinicopathological correlation of the tumor regression grade in neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study.

Authors:  Yi Wang; Handong Xu; Can Hu; Pengcheng Yu; Zhehan Bao; Yanqiang Zhang; Ruolan Zhang; Shengjie Zhang; Bing Li; Jean-Marie Aerts; Zhiyuan Xu; Xiangdong Cheng
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy.

Authors:  Zi-Ning Liu; Yin-Kui Wang; Li Zhang; Yong-Ning Jia; Shan Fei; Xiang-Ji Ying; Yan Zhang; Shuang-Xi Li; Yu Sun; Zi-Yu Li; Jia-Fu Ji
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

3.  Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy.

Authors:  Qi Jiang; Xiangyu Zeng; Chenggang Zhang; Ming Yang; Jun Fan; Gan Mao; Qian Shen; Yuping Yin; Weizhen Liu; Kaixiong Tao; Peng Zhang
Journal:  World J Surg Oncol       Date:  2022-08-17       Impact factor: 3.253

4.  Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer.

Authors:  Ming-Yu Lai; Shi-Yang Kang; Yu-Ting Sun; Ting-Ting Quan; Shi-Xun Lu; Cai-Yun He; Zhi-Wei Zhou; Li-Qiong Yang; Hui-Yan Luo; Feng-Hua Wang; Yu-Hong Li; Rui-Hua Xu; Wen-Long Guan; Miao-Zhen Qiu
Journal:  BMC Cancer       Date:  2022-10-01       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.